antibodies
-
January 9, 2023
Novel lung cancer biomarker
Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer. -
August 25, 2022
Rheumatoid arthritis and heart disease: a common path
An increase in certain antibodies in patients with rheumatoid arthritis can serve as a predictive biomarker for cardiovascular disease, Vanderbilt researchers have discovered. -
March 24, 2022
Grant set to support Georgiev’s research to identify new antibodies
Vanderbilt's Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies. -
March 10, 2022
Technique hastens COVID-19 antibody discovery
Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19. -
January 20, 2022
Omicron evades some but not all monoclonal antibodies: study
A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States. -
December 23, 2021
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19. -
December 9, 2021
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.